Publicacions
-
Xu L, Pierce JL, Sánchez A, Chen KS, Shukla AA, Fustino NJ, Stuart S, Bagrodia A, Krailo MD, Shaikh F, Billmire D, Pashankar F, Bestrashniy J, Wolter Oosterhuis J, Biermann K, Gillis AJM, Stoop J, Xie Y, Teot L, Mora J, Poyter JN, Rakheja D, Looijenga LHJ, Draper BW, Lindsay Frazier A and Armatruda JF.
Integrated genomic analysis reveals aberrations in WNT signaling in germ cell tumours of childhood and adolescence
EUR UROL SUPPL . 18(4): 13-14.
-
Garcia-López M, Rodriguez-Hernandez CJ, Mateo-Lozano S, Pérez-Jaume S, Gonçalves-Alves E, Lavarino C, Mora J and de Torres C.
Parathyroid hormone-like hormone plays a dual role in neuroblastoma depending on PTH1R expression
MOLECULAR ONCOLOGY . 13(9): 1959-1975. Nº de cites: 8
-
Lezama-Del Valle P, Krauel L and LaQuaglia MP.
Error traps and culture of safety in pediatric surgical oncology.
SEMIN PEDIATR SURG . 28(3): 164-171. Nº de cites: 2
-
Mora J, Valero M, DiCristina C, Jin M, Chain A and Bickham K.
Pharmacokinetics/pharmacodynamics, safety, and tolerability of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric cancer patients
PEDIATRIC BLOOD & CANCER . 66(6): . Nº de cites: 8
-
Carvalho D, Taylor KR, Gene-Olaciregui N, Molinari V, Clarke M, Mackay A, Ruddle R, Henley A, Valenti M, Hayes A, Brandon AH, Eccles SA, Raynaud F, Boudhar A, Monje M, Popov S, Moore AS, Mora J, Cruz-Martínez O, Vinci M, Brennan PE, Bullock AN, Carcaboso AM and Jones C.
ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma
Communications Biology . 2: 156-156. Nº de cites: 63
-
Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo H, Ordóñez JL, Dominguez-Hormaetxe S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frias MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler KL, Seifert O, Kontermann RE, Pfizenmaier K, Simon L, Fabre M, Carcaboso AM, Ludwig JA and de Álava E.
Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma
CLINICAL CANCER RESEARCH . 25(7): 2228-2240. Nº de cites: 30
-
Chellapandian D, Hines MR, Zhang R, Jeng M, van den Bos C, Salvador-Marcos N, Lehmberg K, Sieni E, Wang Y, Nakano T, Williams JA, Fustino NJ, Astigarraga I, Dunkel IJ, Abla O, van Halteren AGS, Pei D, Cheng C, Weitzman S, Sung L and Nichols KE.
A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis.
CANCER . 125(6): 963-971. Nº de cites: 18
-
Blanco, AM, Krauel L and Artes, FF.
Development of a patients-specific 3D-printed preoperative planning and training tool, with functionalized internal surfaces, for complex oncologic cases
RAPID PROTOTYPING JOURNAL . 25(2): 363-377. Nº de cites: 17
-
Guenther LM, Dharia NV, Ross L, Saur Conway A, Robichaud AL, Catlett JL, Wechsler C, Frank ES, Goodale AB, Church AJ, Tseng YY, Guha R, McKnight C, Janeway KA, Boehm JS, Mora J, Davis MI, Alexe G, Piccioni F and Stegmaier K.
A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma
CLINICAL CANCER RESEARCH . 25(4): 1343-1357. Nº de cites: 57
-
Pascual-Pastó G, Bazan-Peregrino M, Gene-Olaciregui N, Restrepo-Perdomo CA, Mato-Berciano A, Ottaviani D, Weber K, Correa MG, Paco-Mercader S, Vilà-Ubach M, Cuadrado-Vilanova M, Castillo H, Botteri G, García-Gerique L, Moreno-Gilabert H, Gimenez-Alejandre M, Alonso-Lopez P, Farrera-Sal M, Torres-Manjon S, Ramos-Lozano D, Moreno R, Aerts I, Doz F, Cassoux N, Chapeaublanc E, Torrebadell-Burriel M, Roldan-Molina M, König A, Suñol M, Claverol J, Lavarino C, de Torres C, Fu L, Radvanyi F, Munier FL, Català-Mora J, Mora J, Alemany R, Cascallo M, Chantada G and Carcaboso AM.
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
SCIENCE TRANSLATIONAL MEDICINE . 11(476): 9321. Nº de cites: 63